NCT05578820

Phase 1Interventional

Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.

View on ClinicalTrials.gov ↗

Timeline

Start date: Jan 1, 2022
Primary completion: Dec 31, 2023
Completion date: Dec 31, 2023
First posted: Oct 13, 2022
Last posted: Oct 18, 2023
Enrollment: 12
Arms / groups: 3 / —
Source: AACT · ctgov ingestion

Drugs studied

ganciclovir
stimotimagene copolymerplasmid

Indications studied

Squamous Cell Carcinoma of Head and Neck
Anus Neoplasms
Breast Neoplasms
Uterine Cervical Neoplasms
Melanoma
Penile Neoplasms
Sarcoma
Vulvar Neoplasms

CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.